	US 11,939,328 B2
	Quinoline compounds as inhibitors of KRAS
Qinda Ye, Claymont, DE (US); Matthew McCammant, West Chester, PA (US); Artem Shvartsbart, Wilmington, DE (US); Wenyu Zhu, Wilmington, DE (US); Bin Hu, Garnet Valley, PA (US); Chao Qi, Wilmington, DE (US); Xiaozhao Wang, Mt. Laurel, NJ (US); Wenqing Yao, Wilmington, DE (US); and Alexander Sokolsky, Wilmington, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Oct. 13, 2022, as Appl. No. 18/046,303.
Claims priority of provisional application 63/368,563, filed on Jul. 15, 2022.
Claims priority of provisional application 63/363,270, filed on Apr. 20, 2022.
Claims priority of provisional application 63/279,464, filed on Nov. 15, 2021.
Claims priority of provisional application 63/255,610, filed on Oct. 14, 2021.
Prior Publication US 2023/0144051 A1, May 11, 2023
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)

CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01)]

35 Claims

1. A compound that is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile or a pharmaceutically acceptable salt thereof.